CD4+ T cells against human papillomavirus-18 E7 in patients with high-grade cervical lesions associate with the absence of the virus in the cervix

Immunology

Volumn 131, Issue 1, 2010, Pages 89-98

  Seresini, Samantha ^a,b   Origoni, Massimo ^b   Caputo, Luigi ^b   Lillo, Flavia ^a   Longhi, Renato ^c   Vantini, Simone ^d   Paganoni, Anna Maria ^d   Protti, Maria Pia ^a,b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c CNR   (Italy)

^d POLITECNICO DI MILANO   (Italy)

Author keywords

CD4+ T cells; E6 and E7 proteins; high grade cervical lesions; human papillomavirus type 18

Indexed keywords

PROTEIN E6; PROTEIN E7;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 18; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; TH1 CELL; TH2 CELL; UTERINE CERVIX; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU;

ADENOCARCINOMA; ADULT; CD4-POSITIVE T-LYMPHOCYTES; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; DNA-BINDING PROTEINS; FEMALE; HUMAN PAPILLOMAVIRUS 18; HUMANS; LYMPHOCYTE ACTIVATION; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 77955133219     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2010.03277.x     Document Type: Article

References (35)

1. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002 2 : 342 350.
2. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002 55 : 244 265. (Pubitemid 34293391)
3. Hebner CM, Laimins LA. Human papillomaviruses: basic mechanisms of pathogenesis and oncogenicity. Rev Med Virol 2006 16 : 83 97.
4. Walboomers JM, Jacobs MV, Manos MM et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999 189 : 12 9.
5. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003 348 : 518 527. (Pubitemid 36159887)
6. McLaughlin-Drubin ME, Munger K. The human papillomavirus E7 oncoprotein. Virology 2009 384 : 355 344.
7. Mantovani F, Banks L. The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 2001 20 : 7874 7887.
8. Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 2007 7 : 11 22.
9. Serraino D, Carrieri P, Pradier C et al. Risk of invasive cervical cancer among women with, or at risk for, HIV infection. Int J Cancer 1999 82 : 334 337.
10. Palefsky JM, Minkoff H, Kalish LA et al. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV) -positive and high-risk HIV-negative women. J Natl Cancer Inst 1999 91 : 226 236.
11. Lillo FB, Lodini S, Ferrari D, Stayton C, Taccagni G, Galli L, Lazzarin A, Uberti-Foppa C. Determination of human papillomavirus (HPV) load and type in high-grade cervical lesions surgically resected from HIV-infected women during follow-up of HPV infection. Clin Infect Dis 2005 40 : 451 457.
12. Piersma SJ, Welters MJ, van der Hulst JM et al. Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and -DP as a restriction element. Int J Cancer 2008 122 : 486 494.
13. + T cells from patients with cervical cancer are cross-reactive with the coronavirus NS2 protein. J Virol 2003 77 : 5464 5474.
14. Oerke S, Hohn H, Zehbe I et al. Naturally processed and HLA-B8-presented HPV16 E7 epitope recognized by T cells from patients with cervical cancer. Int J Cancer 2005 114 : 766 778.
15. + T-cell immunity against early antigens E2 and E6. Cancer Res 2004 64 : 5449 5455.
16. Welters MJ, de Jong A, van den Eeden SJ et al. Frequent display of human papillomavirus type 16 E6-specific memory T-helper cells in the healthy population as witness of previous viral encounter. Cancer Res 2003 63 : 636 641.
17. + T-helper 1 immunity in relation to health versus disease. Int J Cancer 2006 118 : 950 956.
18. + T cell immunity against the human papillomavirus-18 E6 transforming protein in healthy donors: identification of promiscuous naturally processed epitopes. Eur J Immunol 2005 35 : 806 815.
19. + T cells from healthy young women. J Gen Virol 2007 88 (Pt 5 1470 1478.
20. + T cells predicts the clinical outcome after surgery in patients with high-grade cervical lesions. J Immunol 2007 179 : 7176 7183.
21. de Gruijl TD, Bontkes HJ, Walboomers JM et al. Differential T helper cell responses to human papillomavirus type 16 E7 related to viral clearance or persistence in patients with cervical neoplasia: a longitudinal study. Cancer Res 1998 58 : 1700 1706.
22. + T-cell responses. Cancer Res 2004 64 : 8761 8766.
23. Kadish AS, Ho GY, Burk RD, Wang Y, Romney SL, Ledwidge R, Angeletti RH. Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia. J Natl Cancer Inst 1997 89 : 1285 1293.
24. Luxton JC, Nath R, Derias N, Herbert A, Shepherd PS. Human papillomavirus type 16-specific T cell responses and their association with recurrence of cervical disease following treatment. J Gen Virol 2003 84 (Pt 5 1063 1070.
25. Steele JC, Mann CH, Rookes S, Rollason T, Murphy D, Freeth MG, Gallimore PH, Roberts S. T-cell responses to human papillomavirus type 16 among women with different grades of cervical neoplasia. Br J Cancer 2005 93 : 248 259.
26. Wang X, Moscicki AB, Tsang L, Brockman A, Nakagawa M. Memory T cells specific for novel human papillomavirus type 16 (HPV16) E6 epitopes in women whose HPV16 infection has become undetectable. Clin Vaccine Immunol 2008 15 : 937 945.
27. + T-cell immune responses correlate with regression of HPV-16-associated high-grade squamous intraepithelial lesions. Clin Cancer Res 2007 13 : 2479 2487.
28. Sturniolo T, Bono E, Ding J et al. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat Biotechnol 1999 17 : 555 561.
29. Curnis F, Gasparri A, Sacchi A, Longhi R, Corti A. Coupling tumor necrosis factor-alpha with alphaV integrin ligands improves its antineoplastic activity. Cancer Res 2004 64 : 565 571.
30. Johnson RA. Applied Multivariate Statistical Analysis. Upper Saddle River : Prentice Hall, 2002.
31. Hollander M. Nonparametric Statistical Methods, 2nd edn. New York : Wiley, 1999.
32. Doan T, Chambers M, Street M, Fernando GJ, Herd K, Lambert P, Tindle R. Mice expressing the E7 oncogene of HPV16 in epithelium show central tolerance, and evidence of peripheral anergising tolerance, to E7-encoded cytotoxic T-lymphocyte epitopes. Virology 1998 244 : 352 364.
33. Doan T, Herd K, Street M, Bryson G, Fernando G, Lambert P, Tindle R. Human papillomavirus type 16 E7 oncoprotein expressed in peripheral epithelium tolerizes E7-directed cytotoxic T-lymphocyte precursors restricted through human (and mouse) major histocompatibility complex class I alleles. J Virol 1999 73 : 6166 6170.
34. + T-cell responses against novel pan-human leukocyte antigen-D region presented human papillomavirus-16 E7 epitopes. Clin Cancer Res 2004 10 : 3301 3308.
35. Okubo M, Saito M, Inoku H, Hirata R, Yanagisawa M, Takeda S, Kinoshita K, Maeda H. Analysis of HLA-DRB1*0901-binding HPV-16 E7 helper T cell epitope. J Obstet Gynaecol Res 2004 30 : 120 129.